AN2 Therapeutics (ANTX) EPS (Basic) (2021 - 2026)
AN2 Therapeutics (ANTX) posted quarterly EPS (Basic) of -$0.29 for Q1 2026, up 16.91% year-over-year from -$0.25 in Q1 2025, and down 2.14% quarter-over-quarter from -$0.29 in Q4 2025.
Powered by 
Analysis
AN2 Therapeutics (ANTX) EPS (Basic) (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has reported EPS (Basic) for 6 consecutive years, with -$0.29 the latest figure, recorded in Q1 2026.
- In Q1 2026, EPS (Basic) rose 16.91% year-over-year to -$0.29; the TTM figure through Mar 2026 stood at -$1.01 (up 32.77% YoY), while the FY2025 annual figure was -$1.16, up 32.34% from the prior year.
- EPS (Basic) eased to -$0.29 in Q1 2026 per ANTX's latest filing, from -$0.29 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$0.21 in Q2 2025 and bottomed at -$2.98 in Q1 2022.
- Historically, EPS (Basic) has averaged -$0.65 across 5 years, with a median of -$0.53 in 2022.
- On a YoY basis, EPS (Basic) climbed as much as 82.53% in 2022 and fell as far as 177.92% in 2022.
- AN2 Therapeutics' EPS (Basic) stood at -$0.77 in 2022, then increased by 7.25% to -$0.72 in 2023, then jumped by 64.78% to -$0.25 in 2024, then slipped by 14.31% to -$0.29 in 2025, then retreated by 2.14% to -$0.29 in 2026.
- Business Quant data shows ANTX's EPS (Basic) at -$0.29 in Q1 2026, -$0.29 in Q4 2025, and -$0.31 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -3.06 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.18 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.06 |
| 10 | AN2 Therapeutics | 262.30 Mn | 262.30 Mn | - | -0.18 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.18 |
| Mar 31, 2026 | -0.29 |
| Dec 31, 2025 | -0.29 |
| Sep 30, 2025 | -0.31 |
| Jun 30, 2025 | -0.21 |
| Mar 31, 2025 | -0.35 |
| Dec 31, 2024 | -0.25 |
| Sep 30, 2024 | -0.43 |
| Jun 30, 2024 | -0.48 |
| Mar 31, 2024 | -0.56 |
| Dec 31, 2023 | -0.72 |
| Sep 30, 2023 | -0.65 |
| Jun 30, 2023 | -0.81 |
| Mar 31, 2023 | -0.79 |
| Dec 31, 2022 | -0.77 |
| Sep 30, 2022 | -0.59 |
| Jun 30, 2022 | -0.53 |
| Mar 31, 2022 | -2.98 |
| Dec 31, 2021 | -3.59 |
| Sep 30, 2021 | -3.35 |